RééDOC
75 Boulevard Lobau
54042 NANCY cedex

Christelle Grandidier Documentaliste
03 83 52 67 64


F Nous contacter

0

Article

--";3! O

-A +A

Predictors of quality of life in women with heart failure

RIEDINGER MS; DRACUP KA; BRECHT ML
J HEART LUNG TRANSPLANT , 2000, vol. 19, n° 6, p. 598-608
Doc n°: 98263
Localisation : Documentation IRR
Descripteurs : HE4 - EVALUATION DE LA REEDUCATION READAPTATION, FA3 - CARDIOPATHIES

Two and one half million women have heart failure (HF). Yet little is known about quality of life (QOL) in this population and the factors influencing it. Given the importance of QOL as an outcome of care, we conducted a study to evaluate predictors of QOL in women with HF. METHODS: Using baseline QOL data collected in the Studies of Left Ventricular Dysfunction (SOLVD) trials, we studied predictors of QOL in 691 women with HF. Univariate, bivariate, and multiple regression analyses were used. Potential predictors included age, education, tobacco use, social isolation, life stresses, comorbidity index, New York Heart Association (NYHA) class, HF symptoms, etiology, and medications. We measured global QOL and QOL dimensions of physical function, emotional distress, and social and general health. RESULTS: Women were older (61+/-10.5 years), predominantly Caucasian (75%), and their mean ejection fraction was 0.27 (+/-6.51). Variables with the strongest relationship to QOL included dyspnea, NYHA class, and life stresses. As dyspnea, life stresses, and NYHA class increased, QOL decreased. Additionally, smoking behavior and vasodilator use was associated with decreased QOL. Heart failure etiology of ischemic origin was associated with decreased social life satisfaction, and use of digitalis was predictive of increased social life satisfaction. Finally, increasing age was related to an increase in general life satisfaction. CONCLUSION: Symptom amelioration, which may improve functional ability, has the greatest potential for increasing QOL in women with HF. Programs to increase physical activity in women with HF should be developed and tested. Finally, clinicians may need to optimize HF medications in women.

Langue : ANGLAIS

Tiré à part : OUI

Identifiant basis : 2001214194

Mes paniers

4

Gerer mes paniers

0